Hepatocellular carcinoma (HCC) is a common tumor worldwide. Its incidence has tripled in the USA during the last 25 years, and its prognosis is very poor. Although the main etiologic factors for HCC are well known, its pathogenesis is poorly understood. Thus, there is an urgent need for studies of the mechanisms of HCC development relevant to the human disease. HCC generally develops in cirrhotic livers in the presence of chronic inflammation, after a long phase consisting of hepatocyte proliferation and apoptosis. Oxidative stress generated in this environment can cause DMA damage that leads to chromosomal instability and disruption of cell cycle checkpoints. We have proposed that chromosomal instability, an almost universal finding in human HCC, may be caused by defects in the non-homologous end-joining (NHEJ) DMA repair pathway for double strand breaks (DSB). We have shown that the lack of the Ku70 component of NHEJ repair pathway accelerates HCC development in mice injected with diethylnitrosamine (DEN), and produces tumors with multiple numeric and structural chromosomal aberrations. A striking feature of tumorigenesis in Ku70-/- mice is the almost complete lack of p53 protein expression without alteration in p53 mRNA levels. We suggest that lack of p53 protein expression is caused by post-translational mechanisms that destabilize p53 through increased Mdm2 binding and proteasomal degradation. In contrast, mice that have a defect in ATM, a major transducer of DNA damage, are completely protected from DEN tumorigenesis for at least 12 months, and show large increases in p53 protein expression. We propose experiments designed to study the mechanisms of accelerated tumorigenesis in Ku70-/- mice, and HCC resistance in Atm-/- mice, and to determine: a) whether HCC development and chromosomal instability associated with Ku70 deficiency can be blocked by proteasome inhibitors and restoration of p53 activity through liver-specific inhibition of Mdm2 activity; b) whether HCC resistance in Atm-/- mice can be abolished by liver specific expression of mutant p53; c) whether human HCC and dysplastic lesions have altered expression of components of the NHEJ repair pathway, and d) whether molecular and karyotype homologies exist between human and Ku70-/- HCCs. The proposed experiments will increase our understanding of the mechanisms of hepatocellular carcinogenesis, and test therapeutic strategies that might be applied to human tumors. ? ? ?

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
2R01CA074131-11
Application #
7199514
Study Section
Cancer Molecular Pathobiology Study Section (CAMP)
Program Officer
Pelroy, Richard
Project Start
1997-05-01
Project End
2011-07-31
Budget Start
2007-09-21
Budget End
2008-07-31
Support Year
11
Fiscal Year
2007
Total Cost
$280,617
Indirect Cost
Name
University of Washington
Department
Pathology
Type
Schools of Medicine
DUNS #
605799469
City
Seattle
State
WA
Country
United States
Zip Code
98195
Wright, Jocelyn H; Johnson, Melissa M; Shimizu-Albergine, Masami et al. (2014) Paracrine activation of hepatic stellate cells in platelet-derived growth factor C transgenic mice: evidence for stromal induction of hepatocellular carcinoma. Int J Cancer 134:778-88
Riehle, Kimberly J; Johnson, Melissa M; Johansson, Fredrik et al. (2014) Tissue-type plasminogen activator is not necessary for platelet-derived growth factor-c activation. Biochim Biophys Acta 1842:318-25
Obayashi, Yoko; Campbell, Jean S; Fausto, Nelson et al. (2013) Impaired lipid accumulation in the liver of Tsc2-heterozygous mice during liver regeneration. Biochem Biophys Res Commun 437:146-50
Fernando, Joan; Sancho, Patricia; Fernandez-Rodriguez, Conrado M et al. (2012) Sorafenib sensitizes hepatocellular carcinoma cells to physiological apoptotic stimuli. J Cell Physiol 227:1319-25
Lai, Keane K Y; Shang, Sufen; Lohia, Neha et al. (2011) Extracellular matrix dynamics in hepatocarcinogenesis: a comparative proteomics study of PDGFC transgenic and Pten null mouse models. PLoS Genet 7:e1002147
Caja, Laia; Bertran, Esther; Campbell, Jean et al. (2011) The transforming growth factor-beta (TGF-?) mediates acquisition of a mesenchymal stem cell-like phenotype in human liver cells. J Cell Physiol 226:1214-23
Riehle, Kimberly J; Dan, Yock Y; Campbell, Jean S et al. (2011) New concepts in liver regeneration. J Gastroenterol Hepatol 26 Suppl 1:203-12
Caja, Laia; Sancho, Patricia; Bertran, Esther et al. (2011) The tyrphostin AG1478 inhibits proliferation and induces death of liver tumor cells through EGF receptor-dependent and independent mechanisms. Biochem Pharmacol 82:1583-92
Vaquero, Javier; Campbell, Jean S; Haque, Jamil et al. (2011) Toll-like receptor 4 and myeloid differentiation factor 88 provide mechanistic insights into the cause and effects of interleukin-6 activation in mouse liver regeneration. Hepatology 54:597-608
Campbell, Jean S; Argast, Gretchen M; Yuen, Sebastian Y et al. (2011) Inactivation of p38 MAPK during liver regeneration. Int J Biochem Cell Biol 43:180-8

Showing the most recent 10 out of 63 publications